Physician profile
Melanne Rosetta
NPI 1265954200
$65,987.74
in general payments reported to CMS, 2019-2025
27 companies · $38K in 2025
The $38K reported for 2025 was more than what 99% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $840 · 2020: $597 · 2021: $1,101 · 2022: $2,736 · 2023: $3,784 · 2024: $19K · 2025: $38K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $38K · Food and Beverage: $11K · Travel and Lodging: $7,904 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $2,800 · Consulting Fee: $1,000 · Education: $198 · Gift: $40.59 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $37,985.00 |
| Food and Beverage | $10,759.78 |
| Travel and Lodging | $7,903.51 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $2,800.00 |
| Consulting Fee | $1,000.00 |
| Education | $197.98 |
| Gift | $40.59 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $46,208.08 | 2023-2025 | Acthar |
| Biotissue Holdings INC. | $8,533.76 | 2022-2025 | |
| Glaukos Corporation | $3,385.79 | 2019-2025 | Photrexa, Photrexa Viscous and Photrexa, Idose |
| Alcon Vision LLC | $1,024.85 | 2022-2025 | Clareon, Rocklatan, Simbrinza |
| Abbvie INC. | $1,006.63 | 2022-2025 | Xen Glaucoma Treatment System, Durysta, Lumigan |
| Bausch & Lomb Americas INC. | $843.89 | 2022-2025 | Envista Mx60 Iol, Toric, Amvisc |
| Rxsight INC | $754.56 | 2022-2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Dompe US, INC. | $692.86 | 2023-2025 | Oxervate |
| Johnson & Johnson Surgical Vision, INC. | $610.33 | 2023-2025 | Tecnis Iol, Tecnis Iol, Tecnis Simplicity |
| Tarsus Pharmaceuticals, INC. | $485.20 | 2024-2025 | Xdemvy |
| Harrow Eye, LLC | $384.60 | 2024-2025 | Vevye, Iheezo |
| Sight Sciences, INC. | $377.39 | 2020-2025 | Tearcare System |
| New World Medical,INC. | $232.70 | 2024 | Kahook Dual Blade, Streamline, Ahmed Glaucoma Valve |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $228.22 | 2019 | |
| Oyster Point Pharma, INC. | $215.76 | 2024-2025 | Tyrvaya, Ryzumvi |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $195.92 | 2020-2021 | |
| Genzyme Corporation | $191.30 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $118.75 | 2020-2022 | |
| Sun Pharmaceutical Industries INC. | $98.92 | 2021-2025 | |
| Ivantis, INC | $92.43 | 2021 | |
| Topcon Healthcare, INC. | $91.14 | 2024 | |
| Kala Pharmaceuticals, INC. | $57.72 | 2021 | |
| Amgen INC. | $47.14 | 2024 | Tepezza |
| Ani Pharmaceuticals, INC. | $36.11 | 2025 | Iluvien |
| Thea Pharma INC. | $35.60 | 2025 | Iyuzeh |
| Genentech USA, INC. | $22.10 | 2025 | Vabysmo |
| Apellis Pharmaceuticals, INC. | $15.99 | 2023 | Syfovre |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melanne Rosetta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.